F-18 FDG PET brain imaging in symptomatic arthroprosthetic cobaltism

• Published in: European journal of nuclear medicine and molecular imaging 2020-07, Vol.47 (8), p.1961-1970
• Main Authors: Bridges, Robert L., Cho, Christina S., Beck, Marc R., Gessner, Bradford D., Tower, Stephen S.
• Format: Article
• Language: English
• Subjects: Arthroplasty, Replacement, Hip; Blood; Brain; Cardiology; Chromium; Cobalt; Cobalt base alloys; Computer programs; Executive function; Fluorine isotopes; Fluorodeoxyglucose F18; Heavy metals; Hip Prosthesis; Humans; Hypometabolism; Imaging; Joints (anatomy); Lability; Level (quantity); Medical imaging; Medicine; Medicine & Public Health; Metabolism; Neuroimaging; Neurology; Nuclear Medicine; Oncology; Original; Original Article; Orthopedics; Patients; Pons; Positron emission; Positron emission tomography; Prostheses; Quantitative analysis; Radioisotopes; Radiology; Sensorimotor system; Software; Statistical analysis; Surgery; Surgical implants; Thalamus; Tomography; Toxicity; Tremor; Urine
• ISSN: 1619-7070; 1619-7089
• DOI: 10.1007/s00259-019-04648-2

Purpose Imaging studies of cobalt toxicity from cobalt-chromium alloy arthroprosthetics have focused on the local intra-articular and peri-articular presentation from failing joint replacements. Most studies investigating neurological findings have been small case series focused on the clinical findings of memory loss, diminished executive function, tremor, hearing and vision loss, depression, and emotional lability. This study utilizes software-based quantitative analysis of brain metabolism to assess the degree of hypometabolism and areas of susceptibility, determine if a pattern of involvement exists, and measure reversibility of findings after prosthetic revision to cobalt-free appliances. Methods Over 48 months, 247 consecutive patients presenting to an orthopedic clinic with an arthroprosthetic joint containing any cobalt-chromium part were screened with whole blood and urine cobalt levels. A clinically validated inventory of 10 symptoms was obtained. Symptomatic patients with a blood cobalt level above 0.4 mcg/L or urine cobalt greater than 1 mcg/L underwent F-18 FDG PET brain imaging. Analysis was performed with FDA-approved quantitative brain analysis software with the pons as the reference region. Control group was the normal brain atlas within the software. Results Of the 247 consecutively screened patients, 123 had blood and urine cobalt levels above the threshold. The 69 scanned patients had statistically significant regional hypometabolism and higher symptoms inventory. Fifty-seven patients were retained in the study. Distribution of hypometabolism was in descending order: temporal, frontal, Broca’s areas, anterior cingulate, parietal, posterior cingulate, visual, sensorimotor, thalamic, and lastly caudate. Metal-on-metal (MoM) and metal-on-plastic (MoP) joint replacements produced similar patterns of hypometabolism. Of 15 patients with necessary revision surgery, 8 demonstrated improved metabolism when later re-scanned. Conclusion All scanned patients had regions of significant hypometabolism. Neurological toxicity from elevated systemic cobalt levels following arthroprosthetic joint replacement has a pattern of regional susceptibility similar to heavy metals and solvents, differing from classical dementias and may occur at blood and urine cobalt levels as low as 0.4 mcg/L and 1 mcg/L, respectively. Presently accepted thresholds for cobalt exposure and monitoring may need revision. Quantitative F-18 FDG PET brain imaging may aid in the decis